Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring

Kwang Meyung Kim, Jong Ho Kim, Hyungkyu Park, Yoo Shin Kim, Kyeongsoon Park, Heayun Nam, Seulki Lee, Jae Hyung Park, Rang Woon Park, In-San Kim, Kuiwon Choi, Sang Yoon Kim, Kinam Park, Ick Chan Kwon

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.

Original languageEnglish
Pages (from-to)219-227
Number of pages9
JournalJournal of Controlled Release
Volume146
Issue number2
DOIs
Publication statusPublished - 2010 Sep 1
Externally publishedYes

Fingerprint

Drug Monitoring
Nanoparticles
Chitosan
Neoplasms
Pharmaceutical Preparations
Paclitaxel
Fluorescent Dyes
Early Detection of Cancer
Antineoplastic Agents

Keywords

  • Chitosan nanoparticle
  • Drug delivery
  • Non-invasive imaging
  • Paclitaxel
  • Theragnosis
  • Tumor homing

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Tumor-homing multifunctional nanoparticles for cancer theragnosis : Simultaneous diagnosis, drug delivery, and therapeutic monitoring. / Kim, Kwang Meyung; Kim, Jong Ho; Park, Hyungkyu; Kim, Yoo Shin; Park, Kyeongsoon; Nam, Heayun; Lee, Seulki; Park, Jae Hyung; Park, Rang Woon; Kim, In-San; Choi, Kuiwon; Kim, Sang Yoon; Park, Kinam; Kwon, Ick Chan.

In: Journal of Controlled Release, Vol. 146, No. 2, 01.09.2010, p. 219-227.

Research output: Contribution to journalArticle

Kim, KM, Kim, JH, Park, H, Kim, YS, Park, K, Nam, H, Lee, S, Park, JH, Park, RW, Kim, I-S, Choi, K, Kim, SY, Park, K & Kwon, IC 2010, 'Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring', Journal of Controlled Release, vol. 146, no. 2, pp. 219-227. https://doi.org/10.1016/j.jconrel.2010.04.004
Kim, Kwang Meyung ; Kim, Jong Ho ; Park, Hyungkyu ; Kim, Yoo Shin ; Park, Kyeongsoon ; Nam, Heayun ; Lee, Seulki ; Park, Jae Hyung ; Park, Rang Woon ; Kim, In-San ; Choi, Kuiwon ; Kim, Sang Yoon ; Park, Kinam ; Kwon, Ick Chan. / Tumor-homing multifunctional nanoparticles for cancer theragnosis : Simultaneous diagnosis, drug delivery, and therapeutic monitoring. In: Journal of Controlled Release. 2010 ; Vol. 146, No. 2. pp. 219-227.
@article{5916cc5a31d34e7e8716bc771276dfda,
title = "Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring",
abstract = "Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.",
keywords = "Chitosan nanoparticle, Drug delivery, Non-invasive imaging, Paclitaxel, Theragnosis, Tumor homing",
author = "Kim, {Kwang Meyung} and Kim, {Jong Ho} and Hyungkyu Park and Kim, {Yoo Shin} and Kyeongsoon Park and Heayun Nam and Seulki Lee and Park, {Jae Hyung} and Park, {Rang Woon} and In-San Kim and Kuiwon Choi and Kim, {Sang Yoon} and Kinam Park and Kwon, {Ick Chan}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.jconrel.2010.04.004",
language = "English",
volume = "146",
pages = "219--227",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Tumor-homing multifunctional nanoparticles for cancer theragnosis

T2 - Simultaneous diagnosis, drug delivery, and therapeutic monitoring

AU - Kim, Kwang Meyung

AU - Kim, Jong Ho

AU - Park, Hyungkyu

AU - Kim, Yoo Shin

AU - Park, Kyeongsoon

AU - Nam, Heayun

AU - Lee, Seulki

AU - Park, Jae Hyung

AU - Park, Rang Woon

AU - Kim, In-San

AU - Choi, Kuiwon

AU - Kim, Sang Yoon

AU - Park, Kinam

AU - Kwon, Ick Chan

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.

AB - Theragnostic multifunctional nanoparticles hold great promise in simultaneous diagnosis of disease, targeted drug delivery with minimal toxicity, and monitoring of treatment. One of the current challenges in cancer treatment is enhancing the tumor-specific targeting of both imaging probes and anticancer agents. Herein, we report tumor-homing chitosan-based nanoparticles (CNPs) that simultaneously execute cancer diagnosis and therapy (cancer theragnosis). These CNPs are unique for their three distinctive characteristics, such as stability in serum, deformability, and rapid uptake by tumor cells. These properties are critical in increasing their tumor targeting specificity and reducing their nonspecific uptake by normal tissues. To develop these CNPs into novel theragnostic nanoparticles, we labeled them with Cy5.5, a near-infrared fluorescent (NIRF) dye, for imaging and also loaded them with paclitaxel (PTX-CNPs), an anticancer drug, for cancer treatment. Cy5.5 labeled PTX-CNPs exhibited significantly increased tumor-homing ability with low nonspecific uptake by other tissues in SCC7 tumor-bearing mice. Theragnostic nanoparticles, Cy5.5 labeled PTX-CNPs, are highly useful for simultaneous diagnosis of early-stage cancer and drug delivery.

KW - Chitosan nanoparticle

KW - Drug delivery

KW - Non-invasive imaging

KW - Paclitaxel

KW - Theragnosis

KW - Tumor homing

UR - http://www.scopus.com/inward/record.url?scp=77955417363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955417363&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.04.004

DO - 10.1016/j.jconrel.2010.04.004

M3 - Article

C2 - 20403397

AN - SCOPUS:77955417363

VL - 146

SP - 219

EP - 227

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -